ALS gets CE certification for PERLA®, a new organ preservation solution, and starts a major clinical trial.

ALS has received CE certification for PERLA®, a first-of-its-kind Preservation and Protection Solution (PPS) designed to actively protect liver and kidney grafts from ischemia-reperfusion injury during transplantation. Unlike traditional cold storage solutions that only slow metabolism, PERLA® uses a combination of pharmacological agents to protect cellular integrity and improve graft recovery. ALS is launching a large randomized clinical trial across Europe with about 500 patients to compare PERLA® against current solutions, aiming to improve transplant outcomes amid changing donor profiles. This marks a significant advancement in organ transplantation technology after over 30 years without major innovation in preservation solutions.